A dipeptidyl peptidase-4 inhibitor but not incretins suppreses abdominal aortic aneurysms in angiotensin II-infused apolipoprotein E-null mice
-
- Kohashi Kyoko
- Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine
-
- Hiromura Munenori
- Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine
-
- Mori Yusaku
- Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine
-
- Terasaki Michishige
- Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine
-
- Watanabe Takuya
- Laboratory of Cardiovascular Medicine, Tokyo University of Pharmacy and Life Sciences
-
- Kushima Hideki
- Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine
-
- Shinmura Kyoko
- Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine
-
- Tomoyasu Masako
- Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine
-
- Nagashima Masaharu
- Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine Hamano Nagashima Clinic
-
- Hirano Tsutomu
- Department of Medicine, Division of Diabetes, Metabolism, and Endocrinology, Showa University School of Medicine
書誌事項
- タイトル別名
-
- A Dipeptidyl Peptidase-4 Inhibitor but not Incretins Suppresses Abdominal Aortic Aneurysms in Angiotensin II-Infused Apolipoprotein E-Null Mice
この論文をさがす
説明
Aim: The main pathophysiology of abdominal aortic aneurysm (AAA) considerably overlaps with that of atherosclerosis. We reported that incretins [glucagon-like peptide (GLP)-1 and glucose-dependent insulinotropic polypeptide (GIP)] or a dipeptidyl peptidase-4 inhibitor (DPP-4I) suppressed atherosclerosis in apolipoprotein E-null (Apoe－/－) mice. Here we investigated the effects of incretin-related agents on AAA in a mouse model.<br>Methods: Apoe－/－ mice maintained on an atherogenic diet were subcutaneously infused with saline, Ang II (2000 ng/kg/min), Ang II, and native GLP-1 (2.16 nmol/kg/day) or Ang II and native GIP (25 nmol/kg/day) for 4 weeks. DPP-4I (MK0626, 6 mg/kg/day) was provided in the diet to the Ang II-infused mice with or without incretin receptor antagonists [(Pro3) GIP and exendin (9-39)].<br>Results: AAA occurred in 70% of the animals receiving Ang II. DPP-4I reduced this rate to 40% and significantly suppressed AAA dilatation, fibrosis, and thrombosis. In contrast, incretins failed to attenuate AAA. Incretin receptor blockers did not reverse the suppressive effects of DPP-4I on AAA. In the aorta, DPP-4I significantly reduced the expression of Interleukin-1β and increased that of tissue inhibitor of metalloproteinase (TIMP)-2. In addition, DPP-4I increased the ratio of TIMP-2 to matrix metalloproteinases-9.<br>Conclusions: DPP-4I, MK0626, but not native incretins has protective effects against AAA in Ang II-infused Apoe－/－ mice via suppression of inflammation, proteolysis, and fibrosis in the aortic wall.
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ
-
Ｊｏｕｒｎａｌ ｏｆ Ａｔｈｅｒｏｓｃｌｅｒｏｓｉｓ ａｎｄ Ｔｈｒｏｍｂｏｓｉｓ 23 (4), 441-454, 2016
一般社団法人 日本動脈硬化学会
